For patients battling the most aggressive forms of blood cancer, a stem cell transplant often represents the final line of defense—the only treatment with the potential to provide a definitive cure. However, the reality of clinical oncology is frequently more complex. Even after the grueling process of a transplant, cancers can and do return, often leaving physicians with a dwindling arsenal of effective options. When a relapse occurs post-transplantation, the prognosis is typically poor, as the patient’s immune system is already compromised and the malignant cells have often developed resistance to standard therapies.
A pioneering clinical trial led by researchers at Washington University School of Medicine in St. Louis suggests a paradigm shift may be on the horizon. The study, recently published in the journal Nature Medicine, demonstrates that genetically modifying donor stem cells before they are transplanted can create a "shield" for the patient’s new immune system. This strategy involves the precise removal of a specific protein from donor cells, a move designed to make follow-up cancer treatments significantly safer and more potent. By rendering healthy transplanted cells invisible to certain therapies, doctors can more aggressively target the remaining cancer cells without the collateral damage that has long hampered such treatments.
The multi-center study was conducted at the Siteman Cancer Center, based at Barnes-Jewish Hospital and WashU Medicine, along with 14 other prominent research sites across the United States and Canada. The findings represent a significant leap forward in the application of gene editing within the field of hematologic oncology.
A Major Challenge for CAR-T Therapy
The primary motivation behind this research is the need to overcome a persistent obstacle in the treatment of myeloid malignancies. While Chimeric Antigen Receptor-T (CAR-T) cell therapy has revolutionized the treatment of certain B-cell lymphomas and leukemias, its success has been frustratingly limited in other areas. Specifically, CAR-T therapy has struggled to gain a foothold against diseases such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
According to the study’s corresponding author, John F. DiPersio, MD, PhD, the Virginia E. & Sam J. Golman Professor of Medicine at WashU Medicine, the bottleneck lies in the shared biology between cancerous and healthy cells. "The problem," DiPersio explained, "is that many proteins found on AML and MDS cancer cells also appear on healthy myeloid cells, including donor stem cells used in transplantation."
In the context of CAR-T therapy, the treatment involves engineering a patient’s own T cells to recognize and attack a specific protein—an antigen—found on the surface of cancer cells. However, if that target protein is also expressed on the surface of healthy blood-forming stem cells, the CAR-T cells cannot distinguish between the "enemy" and the "ally." Consequently, the therapy may systematically destroy the very cells intended to rebuild the patient’s blood and immune systems.
This "off-target" destruction can trigger a cascade of dangerous clinical outcomes. Beyond the immediate loss of healthy blood cells, the conflict can spark a severe inflammatory response. Furthermore, the efficacy of the cancer treatment itself is diluted; when vast numbers of CAR-T cells are occupied attacking healthy targets, fewer are available to concentrate on the malignant cells that threaten the patient’s life.
The conceptual framework for bypassing this biological stalemate was first articulated by Miriam Y. Kim, MD, who is now an assistant professor of medicine at WashU Medicine. Kim’s research journey began as a postdoctoral researcher at the University of Pennsylvania, and she continued to refine the approach within DiPersio’s laboratory before establishing herself as an independent investigator. Today, she treats patients at Siteman Cancer Center, bridging the gap between laboratory innovation and bedside care.
Removing CD33 From Healthy Stem Cells
The focal point of this new clinical strategy is a protein known as CD33. In the trial, patients diagnosed with AML and MDS received donor stem cells that had undergone a sophisticated genetic modification to delete the CD33 protein. The objective was to produce a lineage of healthy blood cells that lacked the specific "hook" that many modern immunotherapies use to latch onto and destroy their targets.
